Analysts Set Denali Therapeutics Inc. (NASDAQ:DNLI) PT at $43.40

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned an average recommendation of “Buy” from the eight brokerages that are currently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $41.22.

A number of research firms recently issued reports on DNLI. Wedbush reiterated an “outperform” rating and set a $31.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, February 28th. HC Wainwright reduced their price target on Denali Therapeutics from $105.00 to $95.00 and set a “buy” rating on the stock in a research report on Wednesday, February 28th. The Goldman Sachs Group lowered their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Finally, UBS Group decreased their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 9th.

Denali Therapeutics Stock Performance

DNLI opened at $17.34 on Wednesday. Denali Therapeutics has a 52-week low of $15.45 and a 52-week high of $33.31. The firm has a market cap of $2.41 billion, a P/E ratio of -16.06 and a beta of 1.33. The business’s fifty day moving average is $19.27 and its 200-day moving average is $19.29.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Tuesday, February 27th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same quarter last year, the firm earned ($0.75) earnings per share. On average, research analysts predict that Denali Therapeutics will post -2.62 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In other news, Director Steve E. Krognes sold 92,500 shares of the stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the sale, the director now directly owns 47,341 shares of the company’s stock, valued at $970,490.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Steve E. Krognes sold 2,750 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $17.29, for a total value of $47,547.50. Following the transaction, the director now owns 139,841 shares in the company, valued at approximately $2,417,850.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $20.50, for a total value of $1,896,250.00. Following the completion of the transaction, the director now directly owns 47,341 shares in the company, valued at approximately $970,490.50. The disclosure for this sale can be found here. Insiders sold a total of 109,289 shares of company stock valued at $2,188,331 over the last three months. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Norges Bank purchased a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $24,736,000. State Street Corp increased its position in Denali Therapeutics by 26.4% in the first quarter. State Street Corp now owns 3,826,792 shares of the company’s stock worth $123,108,000 after buying an additional 799,221 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Denali Therapeutics in the second quarter valued at $18,992,000. Point72 Asset Management L.P. bought a new stake in shares of Denali Therapeutics in the fourth quarter valued at $13,829,000. Finally, BlackRock Inc. lifted its position in shares of Denali Therapeutics by 6.7% during the 2nd quarter. BlackRock Inc. now owns 10,106,275 shares of the company’s stock valued at $298,236,000 after buying an additional 631,878 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.